BACKGROUND: Chronic inflammation and subsequent tissutal alterations may play a key role in prostate carcinogenesis. In this way, molecular alterations of the suppressor of cytokine signaling 3 (SOCS3), one of the most important inhibitory molecule of inflammatory signal transduction circuitries, could contribute to explain the pleiotropic role of interleukin-6 (IL-6) in this type of cancer. METHODS: We analyzed the methylation status and mRNA expression of SOCS3 in 20 benign prostate hyperplasias (BPH) and in 51 prostate cancer specimens. We analyzed the SOCS3 methylation status using methylation-specific PCR. Hypermethylation was confirmed by sequencing after subcloning. Epigenetic silencing of this gene was also demonstrated by real-time PCR and by immunohistochemistry. Results and correlation with clinical data were statistically analyzed. RESULTS: We found that the promoter of SOCS3 was methylated in 39.2% of prostate cancer. On the contrary, all BPH and normal controls had an unmethylated pattern. Real-time analysis showed that in methylated cases SOCS3 mRNA expression was reduced by three and four folds as compared to BPH and unmethylated cases, respectively. Interestingly, SOCS3 mRNA level was higher in unmethylated prostate cancer than in BPH. The immunohistochemical staining analysis for SOCS 3 confirmed mRNA results. Moreover, methylation of SOCS3 promoter significantly associated with intermediate-high grade Gleason score (P = 0.0007) and with an unfavorable clinical outcome (P = 0.0019). CONCLUSIONS: Our data suggest that SOCS3 hypermethylation may be involved in the pathogenesis of prostate cancer and could identify a tumor subset with an aggressive behavior.
BACKGROUND: Chronic inflammation and subsequent tissutal alterations may play a key role in prostate carcinogenesis. In this way, molecular alterations of the suppressor of cytokine signaling 3 (SOCS3), one of the most important inhibitory molecule of inflammatory signal transduction circuitries, could contribute to explain the pleiotropic role of interleukin-6 (IL-6) in this type of cancer. METHODS: We analyzed the methylation status and mRNA expression of SOCS3 in 20 benign prostate hyperplasias (BPH) and in 51 prostate cancer specimens. We analyzed the SOCS3 methylation status using methylation-specific PCR. Hypermethylation was confirmed by sequencing after subcloning. Epigenetic silencing of this gene was also demonstrated by real-time PCR and by immunohistochemistry. Results and correlation with clinical data were statistically analyzed. RESULTS: We found that the promoter of SOCS3 was methylated in 39.2% of prostate cancer. On the contrary, all BPH and normal controls had an unmethylated pattern. Real-time analysis showed that in methylated cases SOCS3 mRNA expression was reduced by three and four folds as compared to BPH and unmethylated cases, respectively. Interestingly, SOCS3 mRNA level was higher in unmethylated prostate cancer than in BPH. The immunohistochemical staining analysis for SOCS 3 confirmed mRNA results. Moreover, methylation of SOCS3 promoter significantly associated with intermediate-high grade Gleason score (P = 0.0007) and with an unfavorable clinical outcome (P = 0.0019). CONCLUSIONS: Our data suggest that SOCS3 hypermethylation may be involved in the pathogenesis of prostate cancer and could identify a tumor subset with an aggressive behavior.
Authors: Hao Yu; Yudong Liu; Braden C McFarland; Jessy S Deshane; Douglas R Hurst; Selvarangan Ponnazhagan; Etty N Benveniste; Hongwei Qin Journal: Cancer Immunol Res Date: 2015-02-03 Impact factor: 11.151
Authors: Peter B Makhov; Konstantin V Golovine; Alexander Kutikov; Daniel J Canter; Vera A Rybko; Dmitry A Roshchin; Vsevolod B Matveev; Robert G Uzzo; Vladimir M Kolenko Journal: Carcinogenesis Date: 2011-09-22 Impact factor: 4.944
Authors: Jana Zeitvogel; Alexander Dalpke; Britta Eiz-Vesper; Michael Kracht; Oliver Dittrich-Breiholz; Thomas Werfel; Miriam Wittmann Journal: J Biol Chem Date: 2012-01-31 Impact factor: 5.157
Authors: Avanti Desai; Mi-Yeon Jung; Ana Olivera; Alasdair M Gilfillan; Calman Prussin; Arnold S Kirshenbaum; Michael A Beaven; Dean D Metcalfe Journal: J Allergy Clin Immunol Date: 2016-01-07 Impact factor: 10.793